Nektar Therapeutics (NKTR) key performance indicators and operating metrics (3 metrics) from SEC EDGAR filings, earnings calls, and investor decks. First-party data.
| Metric | Latest Value | Period |
|---|---|---|
| Total Patients Enrolled in RESOLVE-AA Phase 2b Study | 92.00 | FY2026-Q1 |
| Net Loss (Non-GAAP) | 35M | FY2025-Q3 |
| Basic and Diluted Loss per Share (Non-GAAP) | 1.85 USD_per_share | FY2025-Q3 |
Back to NKTR overview · NKTR earnings · NKTR holders
Data sourced from U.S. SEC EDGAR filings, earnings call transcripts, and investor decks. Not personalized investment advice.